Table of Contents Author Guidelines Submit a Manuscript
International Journal of Analytical Chemistry
Volume 2017, Article ID 2951529, 6 pages
Research Article

In Vitro Dissolution Profile of Dapagliflozin: Development, Method Validation, and Analysis of Commercial Tablets

1Post-Graduation Program in Pharmaceutical Sciences, Department of Pharmacy, Universidade Estadual do Centro-Oeste (UNICENTRO), 85040-080 Guarapuava, PR, Brazil
2Department of Pharmacy, Federal University of Paraná, Curitiba, PR, Brazil

Correspondence should be addressed to Larissa Sakis Bernardi; moc.liamg@bs.assiral

Received 12 April 2017; Accepted 2 July 2017; Published 31 July 2017

Academic Editor: Troy D. Wood

Copyright © 2017 Rafaela Zielinski Cavalheiro de Meira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. R. White, “Sodium glucose cotransporter 2 inhibitors,” Medical Clinics of North America, vol. 99, no. 1, pp. 131–143, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Manasa, K. Dhanalakshmi, R. Nagarjuna, and S. Sreenivasa, “Method development and validation of dapagliflozin in API by RP-HPLC and UV-spectroscopy,” International Journal of Pharmaceutical Science and Drug Research, vol. 6, pp. 250–252, 2014. View at Google Scholar
  3. EUROPEAN MEDICINES AGENCY (EMA), “Assessment report forxiga, procedure Nº. EMEA/H/C/002322, 2012,”
  4. O. Albarran and F. Blasco, “Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2,” Medicina Clínica, vol. 141, pp. 36–43, 2013. View at Google Scholar
  5. Food and Drug Administration (FDA), “FDA approves farxiga® to treat type 2 diabetes,”
  6. Bristol-Myers Squibb. BRASIL, “Anvisa aprova novo medicamento para o tratamento do diabetes tipo 2 que funciona de forma independente da insulina,”
  7. Food and Drug Administration (FDA), “Guidance for Industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms base on a biopharmaceutics classification system, 2000,”
  8. “Harmonized tripartite guideline: Validation of analytical procedures: Text and methodology Q2(R1),” in Proceedings of the International Conference on Harmonisation (ICH), 2005,
  9. The dissolution procedure: Development and validation, vol. 1092, United States Pharmacopeia (USP) 38 Nacional Formulary 33, 2015.
  10. Food and Drug Administration (FDA), “Guidance for industry: Analytical procedures and methods for validation drugs and biologics, 2015,”
  11. BRASIL, Resolução RDC No. 31, de 11 de agosto de 2010. Dispõe sobre a realização dos estudos de equivalência farmacêutica e de perfil de dissolução comparativo, Agência Nacional de Vigilância Sanitária (ANVISA), Brasilia. Brazil, 2010.
  12. J. W. Moore and H. H. Flanner, “Mathematical comparison of dissolution profiles,” Pharmaceutical Technology, vol. 20, no. 6, pp. 64–74, 1996. View at Google Scholar · View at Scopus
  13. BRASIL, Resolução RDC No. 135, de 29 de maio de 2003. Regulamento Técnico Para Medicamentos Genéricos, AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA (ANVISA), Brasília, Brazil, 2003.
  14. K. A. Khan, “The concept of dissolution efficiency,” Journal of Pharmacy and Pharmacology, vol. 27, no. 1, pp. 48-49, 1975. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Karageorgou and V. Samanidou, “Youden test application in robustness assays during method validation,” Journal of Chromatography A, vol. 1353, pp. 131–139, 2014. View at Publisher · View at Google Scholar · View at Scopus